In the 21st century, tumor treatment has entered the era of personalized multidisciplinary comprehensive treatment, and more and more new methods and technologies have been applied to tumor treatment, among which tumor thermotherapy is a hot spot in tumor treatment in recent years, and related research has been reported in the American Society for Clinical Cancer Conference (ASCO) in recent years. In recent years, the relevant studies have been reported in the American Clinical Cancer Conference (ASCO). At present, tumor specialists with certain strengths in China have also carried out tumor thermotherapy to different degrees, and tumor thermotherapy has become a common method of multidisciplinary comprehensive treatment for tumors. Hyperthermia is a kind of tumor treatment method to inactivate tumor cells by increasing the tissue temperature of the body through physical methods. Usually, the tissue temperature reaches 41℃～42℃ and lasts 60～120 minutes to destroy tumor cells without damaging normal tissues. The principle of tumor heat therapy is mainly manifested in three aspects: firstly, the selective effect of heat therapy on tumor tissues. Due to the tortuous and disordered vascular structure of tumor tissues, tumor cells are in hypoxic and low PH environment, which causes tumor tissues to be sensitive to heat, and the temperature of tumor tissues is 3℃~5℃ higher than normal tissues under the same heat, so they are easy to be selectively killed by heat therapy. The second is the direct killing effect of heat therapy on tumor cells. Temperature over 41℃ can induce protein denaturation of tumor cells, causing destruction of cell morphology and function, resulting in cell death. Secondly, heat shock protein is produced on the surface of tumor cells after thermal stimulation. The latter causes rapid lysis and destruction of tumor cells by increasing the sensitivity of tumor cells to natural killer cells on the one hand, and stimulates the body macrophages and dendritic cells to produce immune factors on the other hand, which enhance the inactivation of tumor cells by enhancing cellular immune function. At present, clinical warming is done through three physical methods: ultrasound, electromagnetic field and electromagnetic radiation. The methods of heat therapy used are local heat therapy, regional heat therapy and systemic heat therapy. Local thermotherapy refers to the direct local heating of tumor for the purpose of tumor treatment, which is also divided into extracorporeal thermotherapy, intracavitary thermotherapy and intertissue thermotherapy. Extracorporeal thermotherapy is used to treat superficial tumors, intracorporeal thermotherapy is used to treat tumors with natural lumen such as esophagus and rectum, and intertissue thermotherapy is to directly implant metal electrodes into solid tumors for heating up. Regional thermotherapy adopts techniques such as thermal perfusion to heat body cavities, organs and limbs in a wide range to kill tumors. Whole-body thermotherapy adopts extracorporeal circulation to heat up the blood or heats up the whole body through various forms such as thermal radiation heating bins and hot water blankets to raise the body temperature to 41-42℃ for the purpose of treating tumors, and is used to treat metastatic cancer that has spread to the whole body. The efficacy of thermotherapy is related to the temperature and duration of treatment, as well as the characteristics of the cells or tissues receiving thermotherapy. Currently, most clinical protocols for the delivery of heat therapy are twice a week at a target temperature for one hour. To ensure that the ideal temperature is given to the tumor while not exceeding the normal tolerated temperature in the surrounding tissues, tumor and normal tissue temperature monitoring is required during the treatment period. Adverse reactions in thermotherapy are mostly localized skin “burns” and subcutaneous fat nodules, most of which do not affect the performance of thermotherapy. The application of heat therapy in tumor treatment can be traced back to 1893 when William Coley, an American physician, reported that tumors with hyperthermia would regress, which was the first time that elevated body temperature could effectively treat tumors. In the 1970s, with the advancement of thermotherapy technology, the role of thermotherapy was brought back to the forefront, marked by the First International Congress on Tumor Thermotherapy held in Washington, D.C., in 1975. This congress made tumor thermotherapy quickly come into the attention of the general public and became a popular new method of tumor treatment for a period of time, and papers and conferences on tumor thermotherapy were frequently presented. After that, due to the constraints of thermal therapy technology, some clinical randomized studies failed to achieve the expected effect, and the clinical value of tumor thermal therapy was questioned, and the related thermal therapy research and application also entered a low point. The value of thermotherapy has been reaffirmed, and the NCCN guidelines have also included thermotherapy in the comprehensive treatment plan of certain tumors. The widespread use of thermotherapy in tumor treatment has been attributed to the promotion of multidisciplinary and integrated approach in tumor treatment. A large number of clinical studies have confirmed that thermotherapy has a significant potentiating effect on radiotherapy and chemotherapy, and thermoradiotherapy and thermochemotherapy techniques are a direction to improve the clinical efficacy of comprehensive tumor treatment. The clinical synergistic effect of thermotherapy combined with radiotherapy is currently the most researched area of thermotherapy. Radiotherapy combined with thermotherapy can significantly improve the efficacy of radiotherapy. The mechanism of synergistic effect of thermoradiotherapy is that thermotherapy improves the hypoxia and low PH state of tumor tissues, which increases the sensitivity to radiation, and the denaturation of cellular proteins caused by thermotherapy, which hinders the repair of DNA damaged cells caused by radiation, is the most important mechanism of synergistic effect of thermotherapy combined with radiotherapy. Nowadays, local or regional thermotherapy combined with radiotherapy has become a common integrated treatment option for superficial tumors. The synergistic effect of thermotherapy on chemotherapy is still in the preclinical stage. In vitro tests have shown that the cytotoxic effect of chemotherapeutic drugs is enhanced by thermotherapy, and this synergistic effect of thermochemotherapy varies among different chemotherapeutic drugs. The cytotoxic effects of alkylating agents (cyclophosphamide, isocyclophosphamide), platinum drugs, and nitrosoureas (BCNU, CCNU) increased linearly with temperature as the temperature increased from 37°C to 40°C. Enhanced cytotoxicity of adriamycin and bleomycin required a temperature increase of 42.5°C threshold to occur. In contrast, the cytotoxic effects of antimetabolites (5-fluorouracil, methamidophos), vincristine, and vincristine did not change with temperature. In vivo tests have shown that heat therapy can lead to increased blood flow to tumor tissue, increased drug uptake by tumor cells, increased intracellular drug concentrations, and increased cellular DNA damage. Most of the maximal drug sensitization effects of thermotherapy occur when thermochemotherapy is administered simultaneously. Regional independent limb malfacial thermal perfusion for melanoma has become routine, and prospective randomized clinical trials have demonstrated that this therapy reduces lesion recurrence and improves patient survival. 2007 American Board of Surgical Oncology experts recommended abdominal thermochemotherapy as the standard of care for recurrent metastatic colon cancer or peritoneal metastases from pelvic tumors.